+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Reproductive Health Diagnostics Market Outlook to 2036 - Prenatal Screening and Reproductive Hormones and Proteins Tests

  • PDF Icon

    Report

  • 170 Pages
  • May 2026
  • Region: North America
  • GlobalData
  • ID: 6115325

North America Reproductive Health Diagnostics Market Outlook to 2036 - Prenatal Screening and Reproductive Hormones and Proteins Tests

Summary

The analyst’s “North America Reproductive Health Diagnostics Market Outlook to 2036” is a comprehensive databook report, covering key market data on the North America Reproductive Health Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Prenatal Screening, Reproductive Hormones and Proteins Tests

The North America Reproductive Health Diagnostics Market report provides key information and data on:

  • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2024 to 2036.
  • 2025 company share data for Reproductive Health Diagnostics Market.
  • Global corporate-level profiles of key companies operating within the North America Reproductive Health Diagnostics Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

North America Reproductive Health Diagnostics is segmented as follows:

  • Prenatal Screening
  • Reproductive Hormones and Proteins Tests

Reasons to Buy

The North America Reproductive Health Diagnostics Market report helps you to develop:

  • Business strategies by identifying the key market segments poised for strong growth in the future.
  • Market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

Table of Contents

1 Introduction
1.1 What Is This Report About?
1.2 Reproductive Health Diagnostics Market Segmentation
1.3 Definitions of Markets Covered in the Report
2 Reproductive Health Diagnostics Market, North America
2.1 Reproductive Health Diagnostics Market, North America, Revenue ($m), 2024-2036
2.2 Reproductive Health Diagnostics Market, North America, Revenue ($m), 2024-2036
2.3 Reproductive Health Diagnostics Market, North America, Volume (Units), 2024-2036
2.4 Reproductive Health Diagnostics Market, North America, Volume (Units), 2024-2036
2.5 Reproductive Health Diagnostics Market, North America, Company Share by Revenue ($m), 2025
3 Reproductive Health Diagnostics Market, Canada
3.1 Reproductive Health Diagnostics Market, Canada, Revenue ($m), 2024-2036
3.1.1 Prenatal Screening Market, Canada, Revenue ($m), by Segment, 2024-2036
3.1.2 Reproductive Hormones and Proteins Tests Market, Canada, Revenue ($m), by Segment, 2024-2036
3.2 Reproductive Health Diagnostics Market, Canada, Volume (Units), 2024-2036
3.2.1 Prenatal Screening Market, Canada, Volume (Units), by Segment, 2024-2036
3.2.2 Reproductive Hormones and Proteins Tests Market, Canada, Volume (Units), by Segment, 2024-2036
3.3 Reproductive Health Diagnostics Market, Canada, Average Price ($), 2024-2036
3.4 Reproductive Health Diagnostics Market, Canada, Company Share by Revenue ($m), 2025
4 Reproductive Health Diagnostics Market, Mexico
4.1 Reproductive Health Diagnostics Market, Mexico, Revenue ($m), 2024-2036
4.1.1 Prenatal Screening Market, Mexico, Revenue ($m), by Segment, 2024-2036
4.1.2 Reproductive Hormones and Proteins Tests Market, Mexico, Revenue ($m), by Segment, 2024-2036
4.2 Reproductive Health Diagnostics Market, Mexico, Volume (Units), 2024-2036
4.2.1 Prenatal Screening Market, Mexico, Volume (Units), by Segment, 2024-2036
4.2.2 Reproductive Hormones and Proteins Tests Market, Mexico, Volume (Units), by Segment, 2024-2036
4.3 Reproductive Health Diagnostics Market, Mexico, Average Price ($), 2024-2036
4.4 Reproductive Health Diagnostics Market, Mexico, Company Share by Revenue ($m), 2025
5 Reproductive Health Diagnostics Market, United States
5.1 Reproductive Health Diagnostics Market, United States, Revenue ($m), 2024-2036
5.1.1 Prenatal Screening Market, United States, Revenue ($m), by Segment, 2024-2036
5.1.2 Reproductive Hormones and Proteins Tests Market, United States, Revenue ($m), by Segment, 2024-2036
5.2 Reproductive Health Diagnostics Market, United States, Volume (Units), 2024-2036
5.2.1 Prenatal Screening Market, United States, Volume (Units), by Segment, 2024-2036
5.2.2 Reproductive Hormones and Proteins Tests Market, United States, Volume (Units), by Segment, 2024-2036
5.3 Reproductive Health Diagnostics Market, United States, Average Price ($), 2024-2036
5.4 Reproductive Health Diagnostics Market, United States, Company Share by Revenue ($m), 2025
6 Reproductive Health Diagnostics Market Pipeline Products
6.1 Reproductive Health Diagnostics Market Pipeline Products
6.2 Reproductive Health Diagnostics - Pipeline Products by Stage of Development
6.3 Reproductive Health Diagnostics - Pipeline Products by Segment
6.4 Reproductive Health Diagnostics - Pipeline Products by Territory
6.5 Reproductive Health Diagnostics - Pipeline Products by Regulatory Path
6.6 Reproductive Health Diagnostics - Pipeline Products by Estimated Approval Date
7 Overview of Key Companies in North America Reproductive Health Diagnostics Market
7.1 Illumina Inc
7.1.1 Company Overview
7.2 Quidel Corp
7.2.1 Company Overview
7.3 Beckman Coulter Inc
7.3.1 Company Overview
7.4 Siemens Healthineers AG
7.4.1 Company Overview
7.5 F. Hoffmann-La Roche Ltd
7.5.1 Company Overview
7.6 Danaher Corp
7.6.1 Company Overview
7.7 Abbott Laboratories
7.7.1 Company Overview
7.8 Roche Diagnostics International Ltd
7.8.1 Company Overview
7.9 BGI Genomics Co Ltd
7.9.1 Company Overview
8 Recent Developments
8.1 Corporate Communications
8.1.1 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
8.1.2 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
8.1.3 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager
8.1.4 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
8.1.5 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research
8.1.6 Oct 27, 2025: Aditxt Subsidiary Pearsanta Starts Enrollment in Human Study for Blood-Based Endometriosis Diagnostic
8.1.7 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
8.1.8 Sep 23, 2025: Pictor Secures Funding for U.S. Expansion Through Proteomics Solutions
8.1.9 Sep 15, 2025: Mdxhealth Completes Acquisition of Exosome Diagnostics from Bio-Techne
8.2 Other Significant Developments
8.2.1 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
8.2.2 Nov 09, 2025: Scientific Mechanics Decoded at Vulkan Vegas Casino - South Coast Global Medical Center
8.2.3 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
8.2.4 Oct 30, 2025: Refurbished Vs New Immulite 2000Xpi: Which Is Better for Your Lab
8.2.5 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research
8.2.6 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
8.3 Product News
8.3.1 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV
8.3.2 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
8.3.3 Oct 30, 2025: Refurbished Vs New Immulite 2000Xpi: Which Is Better for Your Lab
8.3.4 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
8.3.5 Oct 27, 2025: Aditxt Subsidiary Pearsanta Starts Enrollment in Human Study for Blood-Based Endometriosis Diagnostic
8.3.6 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
8.3.7 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies
8.3.8 Oct 02, 2025: Hologic Receives FDA Clearance And CE Mark For Automated Molecular Tests To Detect Infectious Gastroenteritis
8.3.9 Sep 19, 2025: Labware Launches Clinical Health Solution 5.06
8.3.10 Sep 10, 2025: PeploBio and Biocode Partner to Launch First Validated Microclot Assay
8.3.11 Sep 08, 2025: Accuro 3S-MIL: Collaborative Innovations For Military Healthcare Applications
8.4 Research And Development
8.4.1 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies
8.5 Strategy And Business Planning
8.5.1 Jan 05, 2026: Reproductive Partners Medical Group Announces Westminster Clinic Expansion to New State of the Art Facility in Long Beach
8.5.2 Nov 25, 2025: US Fertility Forms Strategic Partnership to Accelerate Growth and Expand Access to Advanced Reproductive Care
8.5.3 Nov 11, 2025: Expanse Medical Expands to Providence, Rhode Island
8.5.4 Nov 10, 2025: Synthego Introduces High-Performance Molecular Reagents for Diagnostics
8.5.5 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
8.5.6 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics
8.5.7 Oct 29, 2025: EazeBio And UC Santa Cruz Form Strategic Partnership For Instrument-Free Diagnostics
8.5.8 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research
8.5.9 Sep 23, 2025: Pictor Secures Funding for U.S. Expansion Through Proteomics Solutions
8.5.10 Sep 10, 2025: PeploBio and Biocode Partner to Launch First Validated Microclot Assay
9 Appendix
9.1 Research Methodology
9.1.1 Coverage
9.1.2 Secondary Research
9.1.3 Primary Research
9.1.4 Market Modeling and Forecasting
9.1.5 Company Share Analysis
9.1.6 Benchmarking
9.2 the Analyst Consulting
9.3 Contact Us
9.4 Disclaimer
List of Tables
Table 1: Reproductive Health Diagnostics Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2024-2036
Table 2: Reproductive Health Diagnostics Market, North America, Revenue ($m), USD Constant, 2024-2036
Table 3: Reproductive Health Diagnostics Market, North America, Volume (Units), 2024-2036
Table 4: Reproductive Health Diagnostics Market, North America, Volume (Units), 2024-2036
Table 5: Reproductive Health Diagnostics Market, North America, Company Share by Revenue ($m), 2025
Table 6: Reproductive Health Diagnostics Market, Canada, Revenue ($m), USD Constant, 2024-2036
Table 7: Prenatal Screening Market, Canada, Revenue ($m), USD Constant, 2024-2036
Table 8: Reproductive Hormones and Proteins Tests Market, Canada, Revenue ($m), USD Constant, 2024-2036
Table 9: Reproductive Health Diagnostics Market, Canada, Volume (Units), 2024-2036
Table 10: Prenatal Screening Market, Canada, Volume (Units), 2024-2036
Table 11: Reproductive Hormones and Proteins Tests Market, Canada, Volume (Units), 2024-2036
Table 12: Reproductive Health Diagnostics Market, Canada, Average Price ($), 2024-2036
Table 13: Reproductive Health Diagnostics Market, Canada, Company Share by Revenue ($m), USD Constant, 2025
Table 14: Reproductive Health Diagnostics Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Table 15: Prenatal Screening Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Table 16: Reproductive Hormones and Proteins Tests Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Table 17: Reproductive Health Diagnostics Market, Mexico, Volume (Units), 2024-2036
Table 18: Prenatal Screening Market, Mexico, Volume (Units), 2024-2036
Table 19: Reproductive Hormones and Proteins Tests Market, Mexico, Volume (Units), 2024-2036
Table 20: Reproductive Health Diagnostics Market, Mexico, Average Price ($), 2024-2036
Table 21: Reproductive Health Diagnostics Market, Mexico, Company Share by Revenue ($m), USD Constant, 2025
Table 22: Reproductive Health Diagnostics Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 23: Prenatal Screening Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 24: Reproductive Hormones and Proteins Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 25: Reproductive Health Diagnostics Market, United States, Volume (Units), 2024-2036
Table 26: Prenatal Screening Market, United States, Volume (Units), 2024-2036
Table 27: Reproductive Hormones and Proteins Tests Market, United States, Volume (Units), 2024-2036
Table 28: Reproductive Health Diagnostics Market, United States, Average Price ($), 2024-2036
Table 29: Reproductive Health Diagnostics Market, United States, Company Share by Revenue ($m), USD Constant, 2025
Table 30: Reproductive Health Diagnostics Market Pipeline Products
Table 31: Reproductive Health Diagnostics - Pipeline Products by Stage of Development
Table 32: Reproductive Health Diagnostics Companies - Pipeline Products by Stage of Development
Table 33: Reproductive Health Diagnostics - Pipeline Products by Segment
Table 34: Reproductive Health Diagnostics - Pipeline Products by Territory
Table 35: Reproductive Health Diagnostics - Pipeline Products by Regulatory Path
Table 36: Reproductive Health Diagnostics - Pipeline Products by Estimated Approval Date
Table 37: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country
List of Figures
Figure 1: Reproductive Health Diagnostics Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2024-2036
Figure 2: Reproductive Health Diagnostics Market, North America, Revenue ($m), USD Constant, 2024-2036
Figure 3: Reproductive Health Diagnostics Market, North America, Volume (Units), 2024-2036
Figure 4: Reproductive Health Diagnostics Market, North America, Volume (Units), 2024-2036
Figure 5: Reproductive Health Diagnostics Market, North America, Company Share (%), 2025
Figure 6: Reproductive Health Diagnostics Market, Canada, Revenue ($m), USD Constant, 2024-2036
Figure 7: Prenatal Screening Market, Canada, Revenue ($m), USD Constant, 2024-2036
Figure 8: Reproductive Hormones and Proteins Tests Market, Canada, Revenue ($m), USD Constant, 2024-2036
Figure 9: Reproductive Health Diagnostics Market, Canada, Volume (Units), 2024-2036
Figure 10: Prenatal Screening Market, Canada, Volume (Units), 2024-2036
Figure 11: Reproductive Hormones and Proteins Tests Market, Canada, Volume (Units), 2024-2036
Figure 12: Reproductive Health Diagnostics Market, Canada, Company Share (%), 2025
Figure 13: Reproductive Health Diagnostics Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Figure 14: Prenatal Screening Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Figure 15: Reproductive Hormones and Proteins Tests Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Figure 16: Reproductive Health Diagnostics Market, Mexico, Volume (Units), 2024-2036
Figure 17: Prenatal Screening Market, Mexico, Volume (Units), 2024-2036
Figure 18: Reproductive Hormones and Proteins Tests Market, Mexico, Volume (Units), 2024-2036
Figure 19: Reproductive Health Diagnostics Market, Mexico, Company Share (%), 2025
Figure 20: Reproductive Health Diagnostics Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 21: Prenatal Screening Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 22: Reproductive Hormones and Proteins Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 23: Reproductive Health Diagnostics Market, United States, Volume (Units), 2024-2036
Figure 24: Prenatal Screening Market, United States, Volume (Units), 2024-2036
Figure 25: Reproductive Hormones and Proteins Tests Market, United States, Volume (Units), 2024-2036
Figure 26: Reproductive Health Diagnostics Market, United States, Company Share (%), 2025
Figure 27: Reproductive Health Diagnostics - Pipeline Products by Stage of Development
Figure 28: Reproductive Health Diagnostics - Pipeline Products by Segment
Figure 29: Reproductive Health Diagnostics - Pipeline Products by Territory
Figure 30: Reproductive Health Diagnostics - Pipeline Products by Regulatory Path
Figure 31: Reproductive Health Diagnostics - Pipeline Products by Estimated Approval Date

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Illumina Inc
  • Quidel Corp
  • Beckman Coulter Inc
  • Siemens Healthineers AG
  • F. Hoffmann-La Roche Ltd
  • Danaher Corp
  • Abbott Laboratories
  • Roche Diagnostics International Ltd
  • BGI Genomics Co Ltd